Provided by Tiger Fintech (Singapore) Pte. Ltd.

Biocryst Pharmaceuticals

10.98
-0.0600-0.54%
Volume:3.57M
Turnover:39.30M
Market Cap:2.30B
PE:-42.32
High:11.11
Open:11.01
Low:10.90
Close:11.04
Loading ...

BioCryst reports inducement grants under Nasdaq listing rule

TIPRANKS
·
03 Jun

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
03 Jun

BioCryst Says Orladeyo Prompted 'Significant' Drop Hereditary Angioedema Attacks in Study

MT Newswires Live
·
16 May

BioCryst Pharmaceuticals Says FDA Grants Priority Review for Orladeyo in Children

MT Newswires Live
·
14 May

BRIEF-Biocryst Announces FDA Acceptance Of NDA For Orladeyo (Berotralstat) Oral Granules In Patients With Hereditary Angioedema Aged 2 To 11 Years

Reuters
·
14 May

BioCryst Gets Speedy FDA Review of Pediatric Use of Orladeyo

Dow Jones
·
14 May

BioCryst Pharmaceuticals: Filed Line Extension Application for Use of Orladeyo Oral Granules in Patients With Hae Aged 2-11 Years With Ema

THOMSON REUTERS
·
14 May

BioCryst Pharmaceuticals Inc: FDA Grants Priority Review of Application, With Pdufa Target Action Date of September 12, 2025

THOMSON REUTERS
·
14 May

BioCryst Announces FDA Acceptance of Nda for Orladeyo® (Berotralstat) Oral Granules in Patients With Hereditary Angioedema Aged 2 to 11 Years

THOMSON REUTERS
·
14 May

BioCryst Pharmaceuticals Is Maintained at Equal-Weight by Barclays

Dow Jones
·
07 May

Barclays Sticks to Its Hold Rating for BioCryst (BCRX)

TIPRANKS
·
07 May

Evercore ISI Keeps Their Buy Rating on BioCryst (BCRX)

TIPRANKS
·
07 May

Stock Track | BioCryst Pharmaceuticals Plummets 5.08% Following $30 Million Loan Prepayment

Stock Track
·
07 May

J.P. Morgan Remains a Buy on BioCryst (BCRX)

TIPRANKS
·
06 May

RBC Raises Price Target on BioCryst Pharmaceuticals to $13 From $11, Keeps Outperform Rating

MT Newswires Live
·
06 May

BioCryst Pharmaceuticals Price Target Maintained With a $30.00/Share by HC Wainwright & Co.

Dow Jones
·
06 May

BioCryst Pharmaceuticals Inc : Bofa Global Research Raises Price Objective to $13 From $11

THOMSON REUTERS
·
06 May

BioCryst Pharmaceuticals Is Maintained at Buy by Needham

Dow Jones
·
06 May

BioCryst Pharmaceuticals Soars 23% In One Session - Here's Why It Surprised Investors

Benzinga
·
06 May

Top Midday Gainers

MT Newswires Live
·
06 May